CD3 is a key EHA 2026 target keyword associated with bispecific T-cell engager. It should…
Browsing: competitive landscape
BCL2 is a core target for hematological malignancies, with data across CLL and AML presented…
BTK is a foundational target in B-cell malignancies, with breakthrough data from the BRUIN CLL-322…
FLT3 is a leading target for AML, with the high-profile PASHA trial data presented at…
CD38 is a critical target for multiple myeloma, with new data unveiled at EHA 2026.…
CD7 is a key EHA 2026 target keyword associated with car-t. It should be used…
CD5 is a key EHA 2026 target keyword associated with a t-cell checkpoint/inhibition strategy. It…
CD22 is a key EHA 2026 target keyword associated with allogeneic car-t. It should be…
CD20 remains a cornerstone target for B-cell malignancies, with multiple high-impact trials presented at EHA…
CD19 is a foundational target for B-cell malignancies, with a wealth of data presented at…